Search PubMedSearch

PubMed · 3909061

Immunotherapy failure.

Abstract

A great deal of the immunotherapy failures are preventable if certain criteria are met and guidelines followed. It is mandatory that immunotherapy only be used for those conditions known to be atopic IgE-mediated diseases. With an IgE mechanism established as a foundation for immunotherapy, adherence to certain guidelines (Table 9) will ensure an optimal response to specific therapy. Experience in recent years with in vitro allergy (Table 10) testing in conjunction with or as a replacement for skin testing has resulted in greater efforts as discontinuing immunotherapy previously placed on this treatment, for whom the original diagnosis of allergy cannot be confirmed based on stringent criteria for identifying an IgE-dependent genesis. Too many patients are treated by immunotherapy on the basis of minimal reactions to skin testing or of coincidentally positive skin tests unrelated to the etiology of the patient's complaints.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R G Fadal. 1985. Immunotherapy failure.. https://pubmed.ncbi.nlm.nih.gov/3909061/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Dichotomy of blood- and skin-derived IL-4-producing allergen-specific T cells and restricted V beta repertoire in nickel-mediated contact dermatitis.

In this study we compared the phenotype and cytokine patterns of nickel-specific T cell clones (TCC) derived from blood samples and positive patch test reactions. A total of 252 nickel-specific TCC were established from three nonatopic patients with allergic contact dermatitis caused by nickel. All TCC expressed the TCR-alpha beta, and 77% were CD4+ compared with 21% CD8+ TCC. In contrast to blood-derived TCC, the majority of skin-derived CD4+ or CD8+ T lymphocytes produced IL-4 either in combination with IFN-gamma (type 0 cytokine pattern) or IL-4 exclusively (type 2 pattern). Skin-derived nickel-specific TCC of each patient secreted significantly more IL-4 than blood-derived TCC of the same individual. Analysis of TCR-V beta repertoire from two patients indicated that >40% of the tested TCC expressed one of the following V beta elements: V beta 13.1/13.2, V beta 20, V beta 2, V beta 6.7, or V beta 14. Only 20% of unstimulated T cells but >40% of nickel-stimulated T cells derived from peripheral blood of the same individuals expressed these V beta elements, suggesting a selection of certain TCR-V beta elements by nickel sulfate in these patients. In contrast to the compartmentalization of IL-4 production, there were no major differences in the expression of TCR-V beta elements between blood- and skin-derived nickel-specific TCC. These results point to a modulation of the cytokine production pattern of T lymphocytes after their migration from peripheral blood into the skin and a production of the type 2 cytokine IL-4 in acute eczematous lesions in nonatopic individuals.

Allergens